AVXL

AVXL

USD

Anavex Life Sciences Corp. Common Stock

$11.110-0.070 (-0.626%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$11.180

High

$11.180

Low

$10.870

Volume

0.88M

Company Fundamentals

Market Cap

948.5M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.88M

Exchange

NMS

Currency

USD

52-Week Range

Low $4.93Current $11.110High $14.441

Related News

GlobeNewswire

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for

View more
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for

View more
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
GlobeNewswire

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully enrolled Top line

View more
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
GlobeNewswire

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for

View more
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference